8.61
-0.42 (-4.65%)
| Previous Close | 9.03 |
| Open | 8.85 |
| Volume | 112,803 |
| Avg. Volume (3M) | 217,595 |
| Market Cap | 72,180,000 |
| Price / Book | 9.95 |
| 52 Weeks Range | |
| Earnings Date | 23 Dec 2025 |
| Diluted EPS (TTM) | -12.30 |
| Total Debt/Equity (MRQ) | 131.68% |
| Current Ratio (MRQ) | 0.550 |
| Operating Cash Flow (TTM) | -17.91 M |
| Levered Free Cash Flow (TTM) | -6.55 M |
| Return on Assets (TTM) | -62.86% |
| Return on Equity (TTM) | -244.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Cel-Sci Corporation | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.5 |
| Average | -0.75 |
|
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.98% |
| % Held by Institutions | 3.80% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mai Capital Management | 30 Jun 2025 | 64,933 |
| Archer Investment Corp | 30 Jun 2025 | 1,000 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Oct 2025 | Announcement | CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025 |
| 10 Oct 2025 | Announcement | CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference |
| 29 Aug 2025 | Announcement | CEL-SCI Announces Closing of $10 Million Public Offering |
| 27 Aug 2025 | Announcement | CEL-SCI Announces Pricing of $10 Million Public Offering |
| 27 Aug 2025 | Announcement | CEL-SCI Announces Proposed Public Offering |
| 14 Aug 2025 | Announcement | CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results |
| 13 Aug 2025 | Announcement | CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |